Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
NASDAQ:ACRV ) recently shelled out US$82k to buy stock, at US$1.68 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. In fact, the recent purchase by Peter Blume-Jensen was the biggest purchase of Acrivon Therapeutics shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of US$1.98. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. In the last twelve months Acrivon Therapeutics insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer TreatmentPR Newswire
- Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International CongressGlobeNewswire
- Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACRV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11GlobeNewswire
ACRV
Earnings
- 5/14/25 - Beat
ACRV
Analyst Actions
- 11/25/25 - HC Wainwright
ACRV
Sec Filings
- 1/21/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- ACRV's page on the SEC website